Journal
BLOOD
Volume 137, Issue 8, Pages 1011-1012Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020009269
Keywords
-
Categories
Ask authors/readers for more resources
The study identified two subtypes of DLBCL tumors with CNS recurrence: the hc-MCD subtype resembling PCNSL, and the high-grade tumors characterized by double-hit biology or TP53 mutations.
In this issue of Blood, Ollila et al(1) address a challenging problem: Can the risk for central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) be predicted better on a molecular basis? The authors found that most tumors with CNS recurrence are well defined molecularly and fall into 2 categories. The most frequent is the hc-MCD subtype, based on MYD88L265P and CD79B mutations, which molecularly resembles primary central nervous system lymphoma (PCNSL). Its association with some extranodal disease sites suggests that the molecular underpinning is the major factor driving the increased risk of CNS invasion. The second subgroup encompasses high-grade tumors characterized by double-hit biology or TP53 mutations, which frequently exhibit high-grade B-cell lymphoma signature on gene expression profiling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available